Citation Impact
Citing Papers
Topical tofacitinib for atopic dermatitis: a phase II a randomized trial
2016
Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review
2023 Standout
Cytokines in inflammatory bowel disease
2014 Standout
Psoriasis
2014
A melanocortin receptor 1 and 5 antagonist inhibits sebaceous gland differentiation and the production of sebum-specific lipids
2011
The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin
2005 Standout
Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: A single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers
2010
ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice
2009
Rheumatoid arthritis
2016 Standout
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
2015
MC4R Agonists: Structural Overview on Antiobesity Therapeutics
2018 StandoutNobel
Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents
2005 Standout
Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction
2006
JAKs and STATs in Immunity, Immunodeficiency, and Cancer
2013
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy
2005 Standout
Psoriasis
2021 Standout
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
2012
The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer
2014
cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action
2010 Standout
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Crohn's disease
2016 Standout
JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
2017
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
Efficacy of Sildenafil Citrate at 12 Hours after Dosing: Re-exploring the Therapeutic Window
2004
Ulcerative colitis
2016 Standout
The use of spirocyclic scaffolds in drug discovery
2014 Standout
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis
2020
Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive
2005
Current Treatment Strategies Against Multidrug-Resistant Bacteria: A Review
2022
Drug interactions between hormonal contraceptives and psychotropic drugs: a systematic review
2016
10 Years of GWAS Discovery: Biology, Function, and Translation
2017 Standout
Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction
2002
Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial
2015
Biological Therapies for Atopic Dermatitis: A Systematic Review
2021
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
2013
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
2017 Standout
Opportunities and Challenges in Developing Stearoyl-Coenzyme A Desaturase-1 Inhibitors as Novel Therapeutics for Human Disease
2013
Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
2014
Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals
2014 Standout
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
2015
Psoriasis Pathogenesis and Treatment
2019 Standout
Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
2002
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
2018
U.S. Medical Eligibility Criteria for Contraceptive Use, 2016
2016 Standout
JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines
2015
Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases
2020
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Inflammatory responses and inflammation-associated diseases in organs
2017 Standout
Therapeutic Potential of Phosphodiesterase 5 Inhibition for Cardiovascular Disease
2003
Drug Interactions With Phosphodiesterase-5 Inhibitors Used for the Treatment of Erectile Dysfunction or Pulmonary Hypertension
2010
Works of Jane Harness being referenced
The effects of sildenafil on human sperm function in healthy volunteers
2002
Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality
2002
Ziprasidone and the pharmacokinetics of a combined oral contraceptive
2000
The effects of steady‐state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers
2002
Can sebum reduction predict acne outcome?
2010
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
2012
Tofacitinib (CP ‐690,550), an oral Janus kinase inhibitor, improves patient‐reported outcomes in a phase 2b, randomized, double‐blind, placebo‐controlled study in patients with moderate‐to‐severe psoriasis
2013
Dose Response and Pharmacokinetics of Tofacitinib (CP‐690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis
2013
Brilacidin, a Non-Peptide Defensin-Mimetic Molecule, Inhibits SARS-CoV-2 Infection by Blocking Viral Entry.
2022
Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment
2013